<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168181">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01925599</url>
  </required_header>
  <id_info>
    <org_study_id>BAP101</org_study_id>
    <nct_id>NCT01925599</nct_id>
  </id_info>
  <brief_title>BAP1 Testing in Instance Choroidal Nevi</brief_title>
  <official_title>Identification of Germline BAP1 Mutation in Young Patients With Choroidal Nevi</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amy C Schefler, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Greater Houston Retina Research</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BAP1 serum germline, is a simple blood test in patients with nevi. This study aims to
      examine the rate of germline BAP1 mutations in young patients diagnosed with choroidal nevi
      to explore the role for this test as a screening tool in the future in this particular
      patient population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A germline BAP1 mutation predisposes a person to developing uveal melanoma and other
      cancers. If a mutation is discovered, it changes the approach of managing the nevi. A
      &quot;normal&quot; case of an choroidal nevus involves less frequent follow up visits and in this
      time, the nevi could grow quickly. Closer follow up and more aggressive treatment could
      preserve the patient's vision and potentially prevent micrometastatic spread. This new
      screening technique will be able to extend the length and quality of life of patients with
      more frequent targeted cancer screens.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Examine the rate of germline BAP1 mutations in young patients, diagnosed with choroidal nevi</measure>
    <time_frame>1 Year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Choroidal Nevi</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients age 18 and over and under age 65, diagnosed with choroidal nevi
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        any person with choroidal nevi

        Exclusion Criteria:

        any persons under the age of 18 and over the age of 65
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy C. Schefler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Consultants of Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy C Schefler, MD</last_name>
    <phone>713-524-3434</phone>
    <email>acsmd@houstonretina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lesli Kao, BS</last_name>
    <phone>713-524-3434</phone>
    <email>leslie.kao@houstonretina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Kao, BS</last_name>
      <phone>713-524-3434</phone>
      <email>leslie.kao@houstonretina.com</email>
    </contact>
    <contact_backup>
      <last_name>Karri Schuetzle</last_name>
      <phone>713-524-3434</phone>
      <email>karri.schuetzle@houstonretina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Amy C Schefler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011 Sep;118(9):1881-5. doi: 10.1016/j.ophtha.2011.01.040. Epub 2011 Jun 24. Review.</citation>
    <PMID>21704381</PMID>
  </reference>
  <reference>
    <citation>Singh AD, Kalyani P, Topham A. Estimating the risk of malignant transformation of a choroidal nevus. Ophthalmology. 2005 Oct;112(10):1784-9. Review.</citation>
    <PMID>16154197</PMID>
  </reference>
  <reference>
    <citation>Jensen DE, Rauscher FJ 3rd. Defining biochemical functions for the BRCA1 tumor suppressor protein: analysis of the BRCA1 binding protein BAP1. Cancer Lett. 1999 Sep;143 Suppl 1:S13-7. Review.</citation>
    <PMID>10546591</PMID>
  </reference>
  <reference>
    <citation>Ventii KH, Devi NS, Friedrich KL, Chernova TA, Tighiouart M, Van Meir EG, Wilkinson KD. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res. 2008 Sep 1;68(17):6953-62. doi: 10.1158/0008-5472.CAN-08-0365.</citation>
    <PMID>18757409</PMID>
  </reference>
  <reference>
    <citation>Matatall KA, Agapova OA, Onken MD, Worley LA, Bowcock AM, Harbour JW. BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma. BMC Cancer. 2013 Aug 5;13(1):371. [Epub ahead of print]</citation>
    <PMID>23915344</PMID>
  </reference>
  <reference>
    <citation>Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, Hovland P, Davidorf FH. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 2011 Dec;48(12):856-9. doi: 10.1136/jmedgenet-2011-100156. Epub 2011 Sep 22.</citation>
    <PMID>21941004</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 4, 2014</lastchanged_date>
  <firstreceived_date>August 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Greater Houston Retina Research</investigator_affiliation>
    <investigator_full_name>Amy C Schefler, MD</investigator_full_name>
    <investigator_title>Director of Ophthalmic Oncology</investigator_title>
  </responsible_party>
  <keyword>Nevus</keyword>
  <keyword>Choroidal Melanoma</keyword>
  <keyword>BAP1 mutation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nevus</mesh_term>
    <mesh_term>Nevus, Pigmented</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
